Form 8-K AYTU BIOPHARMA, INC For: Sep 14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
| |||
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
| Trading Symbol(s) |
| Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On September 14, 2022 Aytu BioPharma, Inc. announced the addition of a fourth patent to the intellectual property suite surrounding AR101/Enzastaurin. This fourth patent, licensed from Johns Hopkins University, is titled “Pathway Targets for the Treatment of Vascular Ehlers-Danlos Syndrome,” expands the scientific evidence of the pathophysiology of Vascular Ehlers-Danlos Syndrome (VEDS) and is highly confirmatory of the therapeutic approach for AR101/Enzastaurin. The patent has an expiry date of September 2041, assuming no patent term extensions.
Item 9.01. Financial Statements and Exhibits.
(d) | ||
Exhibits |
| Item |
99.1 | ||
104 | Cover Page Interactive Data File (formatted as inline XBRL). |
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Transflo Wins 2024 Top Workplaces Culture Excellence Awards for Innovation, Work-Life Flexibility, Leadership
- Unigold Inc: TSX-V Approves Warrant Extension
- Tanqueray Nº TEN’s Tiny TEN Emerges as the Cocktail of Milan Design Week, with Over Ten Thousand Served
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!